Abstract: One aspect of the present invention provides an anti-obesity agent, an anti-dementia agent, a deodorant, an anti-aging agent, an anti-glycation agent, an anti-type I allergy agent, a hypotensive agent, a flavor improving agent, a muscle enhancing agent, and a bone metabolism improving agent which contain a bagasse decomposition extract as an active ingredient.

Abstract: One aspect of the present invention provides an anti-obesity agent, an anti-dementia agent, a deodorant, an anti-aging agent, an anti-glycation agent, an anti-type I allergy agent, a hypotensive agent, a flavor improving agent, a muscle enhancing agent, and a bone metabolism improving agent which contain a bagasse decomposition extract as an active ingredient.

Abstract: According to an aspect of the present invention, there is provided an anti-I-type allergy agent including: p-coumaric acid as an active ingredient. In addition, according to another aspect of the present invention, there is provided an anti-dementia agent including: p-coumaric acid as an active ingredient.

Abstract: The present invention provides a Peyer's patch activator containing a polysaccharide obtained from sugar cane as an active ingredient, wherein the polysaccharide contains ?-glucan as a main component and has a peak molecular weight within a range of 720,000 to 1,080,000, with a proportion of glucose in all component sugars being 80% or more, and proportions of nonreducing terminal glucose and ?-1,6-linked glucose being 20 to 30% and 15 to 25%, respectively.

Abstract: The present invention provides a Peyer's patch activator containing a polysaccharide obtained from sugar cane as an active ingredient, wherein the polysaccharide contains ?-glucan as a main component and has a peak molecular weight within a range of 720,000 to 1,080,000, with a proportion of glucose in all component sugars being 80% or more, and proportions of nonreducing terminal glucose and ?-1,6-linked glucose being 20 to 30% and 15 to 25%, respectively.

Abstract: Disclosed is a complex which comprises a carbon nanotube and a modified polysaccharide having a backbone chain with the side thereof being introduced with monosaccharide or oligosaccharide residues. The polysaccharide is preferably ?-1,3-glucan. The complex is prepared by admixing a solution of the modified polysaccharide dissolved in an aprotic polar solvent or a strong alkali solution with an aqueous dispersion of the carbon nanotube, and incubating the mixture.

Abstract: Disclosed is a new type of immunostimulating agent including an immunostimulating oligonucleotide complexed with a carrier which is safe and has a high transfection effect. The carrier complexed with the immunostimulating oligonucleotide to form the immunostimulating agent is a polysaccharide having ?-1,3-bonds (preferably ?-1,3-glucan such as schizophyllan). A preferred example of the immunostimulating oligonucleotide is one containing an unmethylated CpG motif. The polysaccharide for use is preferably modified with nucleic acid-binding functional group and/or cell membrane-affinitive functional group.

Abstract: Disclosed are gene carriers utilizing ?-1,3-glucan and methods of preparing the same. The ?-1,3-glucan has at least one 1,6-glucopyranoside branch and is chemically modified through periodate oxidation and reductive amination so as to impart nucleic acid-binding functional groups (for example, cationic functional groups) to at least some of the 1,6-glucopyranoside branches thereof. Triple helix ?-1,3-glucan is dissolved in a polar organic solvent to form single-stranded ?-1,3-glucan. By replacing, in the presence of a nucleic acid, the polar organic solvent for the solution containing the chemically modified single-stranded ?-1,3-glucan by water, a complex (gene carrier) is formed in which the nucleic acid is bound to double-stranded ?-1,3-glucan.

Abstract: Disclosed is a new type of immunostimulating agent including an immunostimulating oligonucleotide complexed with a carrier which is safe and has a high transfection effect. The carrier complexed with the immunostimulating oligonucleotide to form the immunostimulating agent is a polysaccharide having ?-1,3-bonds (preferably ?-1,3-glucan such as schizophyllan). A preferred example of the immunostimulating oligonucleotide is one containing an unmethylated CpG motif. The polysaccharide for use is preferably modified with nucleic acid-binding functional group and/or cell membrane-affinitive functional group.

Abstract: Disclosed is a complex which comprises a carbon nanotube and a modified polysaccharide having a backbone chain with the side thereof being introduced with monosaccharide or oligosaccharide residues. The polysaccharide is preferably ?-1,3-glucan. The complex is prepared by admixing a solution of the modified polysaccharide dissolved in an aprotic polar solvent or a strong alkali solution with an aqueous dispersion of the carbon nanotube, and incubating the mixture.

Abstract: Disclosed are gene carriers utilizing ?-1,3-glucan and methods of preparing the same. The ?-1,3-glucan has at least one 1,6-glucopyranoside branch and is chemically modified through periodate oxidation and reductive amination so as to impart nucleic acid-binding functional groups (for example, cationic functional groups) to at least some of the 1,6-glucopyranoside branches thereof. Triple helix ?-1,3-glucan is dissolved in a polar organic solvent to form single-stranded ?-1,3-glucan. By replacing, in the presence of a nucleic acid, the polar organic solvent for the solution containing the chemically modified single-stranded ?-1,3-glucan by water, a complex (gene carrier) is formed in which the nucleic acid is bound to double-stranded ?-1,3-glucan.